Clinical trial · no report yet · Phase 2
FLAME
Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L Osimertinib
- NCT04769388 ↗
- Completed
- Beijing Cancer Prevention & Treatment Society
- 3 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- The Efficacy and Safety of Osimertinib Plus Carboplatin and Pemetrexed Versus Osimertinib Monotherapy in Metastatic EGFRm NSCLC Patients With EGFRm Persistence in ctDNA at 3 Weeks After 1L Osimertinib: A Multicenter, Randomized Controlled Study
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Osimertinib; Pemetrexed/Carboplatin
- Arms
- Osimertinib 80 mg QD and platinum-based chemotherapy · Experimental
- Osimertinib 80mg QD · Active comparator
- Enrollment
- 80
- Primary outcomes
- Progression free survival
- Sponsor
- Beijing Cancer Prevention & Treatment Society with Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Dec 28, 2021
- Primary completion
- Jan 24, 2026
- Results posted
- No
- Registry record
- NCT04769388 · updated Aug 12, 2026